Page contentsPage contents Key facts Decision Key facts Active substance itepekimab Therapeutic area Respiratory, thoracic and mediastinal disorders Decision number EMA/PE/0000229841 PIP number EMA/PE/0000229841 Pharmaceutical form(s) Solution for injection Condition(s) / indication(s) Treatment of nasal polyposis Route(s) of administration Subcutaneous use Contact for public enquiries Sanofi Winthrop Industrie Email: contact-us@sanofi.comTel: +31 202 453 703 Decision type W: decision granting a waiver in all age groups for all conditions or indications Decision date 21/03/2025 Compliance check done No Decision EMA/PE/0000229841 : EMA decision of 21 March 2025 on the granting of a product specific waiver for itepekimabAdopted Reference Number: EMADOC-1700519818-1980448 English (EN) (229.6 KB - PDF)First published: 04/06/2026 View Share this page